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Abstract: Ghrelin, a newly discovered bioactive peptide, is a natural endogenous ligand of the growth hormone (GH) 
secretagogue receptor and initially identified as a strong stimulant for the release of GH. Subsequent research has shown 
that ghrelin and its various receptors are ubiquitous in many other organs and tissues. Moreover, they participate in the 
regulation of appetite, energy, bodyweight, metabolism of glucose and fat, as well as modulation of gastrointestinal, 
cardiovascular, pulmonary, immune functions and cell proliferation/apoptosis. Increasing evidence has demonstrated that 
ghrelin has a close relationship with cardiovascular system. Ghrelin and its receptors are widely distributed in 
cardiovascular tissues, and there is no doubt that the effects of ghrelin in the cardiovascular system are mediated not only 
via its growth-hormone-releasing effect but also by its direct effects on the heart. Exogenous administration of ghrelin can 
dilate peripheral blood vessels, constrict coronary artery, improve endothelial function, as well as inhibit myocardial cell 
apoptosis. So, ghrelin may have cardiovascular protective effect, including lowering of blood pressure, regulation of 
atherosclerosis, and protection from ischemia/reperfusion injury as well as improving the prognosis of myocardial 
infarction and heart failure. Some of these new functions of ghrelin may provide new potential therapeutic opportunities 
for ghrelin in cardiovascular medicine. In this paper, we will review the existing evidence for cardiovascular effects of 
ghrelin, including the cardiovascular function, the variations in ghrelin plasma levels in pathophysiologicalogical 
conditions, the possible protective mechanisms of ghrelin, as well as its future potential therapeutic roles. 
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INTRODUCTION
  Ghrelin, a peptide of 28 amino acids, was first reported 
by Kojima in rat and human stomachs in 1999 [1]. The ripe 
peptide of ghrelin is cleaved from its precursor preproghrelin 
and the gene encoding human preproghrelin is located on 
chromosome 3p25-26 [2]. Then serine-3 of ghrelin is acy-
lated with Ghrelin O-Acyltransferase (GOAT) [3] and this 
esterification is essential for its activity. Two thirds of the 
circulating ghrelin originates in X/A-like cells of the oxyntic 
mucosa of the stomach and rest produced by X/A-like cells 
of the small intestine [4]. In addition, smaller amounts of 
ghrelin is also produced by other organs, such as heart, lung, 
kidney, pancreas, placenta, lymphatic tissue, gonads, thyroid, 
adrenal, pituitary, hypothalamus, and some neoplastic tissues 
and cancer-cell lines [2, 5-11]. 
  In healthy adults plasma, the acyl-ghrelin is 10~20fmol/ 
ml, and the total ghrelin (both acyl-ghrelin and non-acyl-
ghrelin) is 100~150fmol/ml [2]. The half-life of ghrelin in 
circulation is less than 60 min, and ghrelin released from 
internal organs is very important for maintaining the plasma 
concentration [12]. While, ghrelin is seen in the cerebral 
spinal fluid but at much lower concentration, about 1/30-
1/40 of that of circulating ghrelin [13].  
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  As the endogenous ligand of the growth hormone secre-
tagogue receptor (GHS-R), ghrelin was initially identified to 
be a strong stimulant for the release of GH [14]. In 
subsequent research ghrelin and its various receptors were 
found ubiquitous in many organs and tissues. Moreover, they 
participate in the regulation of appetite, energy, bodyweight, 
metabolism of glucose and fat, as well as modulation of 
gastrointestinal, cardiovascular, pulmonary and immune 
functions, cell proliferation/apoptosis [15, 16]. Although 
ghrelin and GHS-R1a knockout animals look similar in 
appearance to wild-type animals, may suggesting that ghrelin 
does not play a essential role in growth and development 
[17], both administration of exogenous ghrelin and ghrelin 
gene over expression exhibits increased circulating ghrelin 
accompanied with increased bioactive effect or some 
therapeutic effects. In this paper, we will review the existing 
evidence for cardiovascular effects of ghrelin, including the 
cardiovascular function, the variations in ghrelin plasma 
levels in pathophysiologicalogical conditions, the possible 
protective mechanisms of ghrelin, as well as its future 
potential therapeutic roles. 
CARDIOVASCULAR DISTRIBUTION OF GHRELIN 
AND ITS RECEPTORS  
  As a cardiovascular hormone, ghrelin and its receptors 
widely exist in cardiovascular system. Maria and his co-
investigators found the expression of ghrelin mRNA in 
cultured HL-1 cell line (a kind of adult mouse cardiomyo-
cyte) by reverse transcription polymerase chain reaction Ghrelin and Cardiovascular Diseases  Current Cardiology Reviews, 2010, Vol. 6, No. 1    63 
(RT-PCR), and the expression of ghrelin peptide in HL-1 
and human cardiomyocytes by immunohistochemistry and in 
the cultured medium of these cells by radioimmunity assay 
[18], suggesting ghrelin may exert paracrine/autocrine 
effects in cardiovascular system. Gnanapavan and colleagues 
found the expression of ghrelin mRNA in human atrium and 
myocardium by both classical and real-time RT-PCR [11]. In 
addition, immunocytochemistry evidences indicated that 
ghrelin can be synthesized by human vascular endothelial 
cells [19]. 
  The best investigated ghrelin receptor, GHS-R1a, is 
found on the surface of isolated human cardiomyocytes and 
the HL-1 cell line [18]. The human myocardium and aorta 
also extensively express GHS-R1a [11], although to a much 
lower degree than the pituitary. GHS-R1b mRNA, another 
transcript from the identical gene of GHS-R1a, is likewise 
highly expressed in human myocardium [11], but the 
physiological function of this receptor subtype is yet to be 
determined. An unknown subtype of ghrelin receptor, dis-
tinct from GHS-R1a and GHS-R1b, is found in H9C2 
cardiomyocytes and endothelial cells, and this particular 
ghrelin receptor has the same binding affinity to either 
acylated or non-acylated ghrelin [20]. In addition, CD36, a 
type B scavenger receptor of a 84 kD glycoprotein, is 
expressed in rat and human cardiovascular tissues [21-23] 
,and can covalently bind to synthetic peptidyl GHSs, such as 
[
125I]Tyr-Ala-hexarelin. However, the potential relationship 
between ghrelin and CD36 requires further studies. Using a 
[
125I]His9-ghrelin binding assay, the pervasiveness of GHS 
receptors in the cardiovascular system has been confirmed in 
the human saphenous veins, aorta, coronary artery, left 
ventricle, and right atrium [24]. Different subtypes of ghrelin 
receptors vary in their biological effects on heart and blood 
vessels. 
CARDIOVASCULAR EFFECTS OF GHRELIN 
1) Vascular Effects of Ghrelin 
  In healthy volunteers, single intravenous bolus of human 
ghrelin (10 g/kg) significantly decreased the mean arterial 
pressure (MAP) [25]. Ghrelin level has been observed to 
positively correlate with micro vascular flow rate [26]. The 
ghrelin’s effect on blood vessels is closely related to nitric 
oxide (NO). Ghrelin stimulates NO production in bovine 
aortic endothelium in a time and dose dependent fashion 
[27]. In human aortic endothelial cells, ghrelin promotes NO 
synthesis by GHSR-1a, phosphoinositide-3 (PI3K), Akt, and 
endothelial NO synthetase (eNOS) pathways [27]. In GH-
deficient rats, ghrelin enhances the maximal relaxation of the 
aortic ring and expression of the eNOS in the aorta, and this 
effect can be inhibited by non-selective NOS inhibitors [28].  
  However, in cultured human umbilical vein endothelial 
cells (HUVEC), ghrelin may modulate the vascular tone by 
negative regulation of mRNA expression of prostaglandin-
endoperoxide synthase-2 (COX2), eNOS, and inducible NO 
synthetase (iNOS) [29]. Another report suggested that 
ghrelin exerts its contractile activity on guinea-pig renal 
arteries by facilitation of endothelin-1(ET-1) triggered intra-
cellular signaling in smooth muscle cell, including phos-
pholipase C (PLC), Rho-kinase, and intracellular IP3-
sensitive Ca
2+ release, and/or by stimulating the release of an 
unknown contractile mediator from the endothelium [30]. 
Given earlier reports showing the direct vasodilatory effects 
on endothelium exfoliated blood vessels [31] and contractile 
effects on coronary arteries [32, 33], the vascular effects of 
this peptide is quite complex and variable.  
2) Endothelium Protective Effect of Ghrelin 
  Application of exogenous ghrelin can improve the 
impaired endothelium function of patients with metabolic 
syndrome (MS) by increasing NO bioactivity [34]. Ghrelin is 
also able to suppress high glucose-induced vascular endo-
thelial cells (ECV-304) apoptosis by activating PI3K/Akt 
ways and reducing reactive oxygen species (ROS) generation 
[35]. In addition, ghrelin can inhibit inflammatory response 
of HUVEC [36] and migration of human aortic endothelial 
cells (HAEC)[37].  
3) Cardiac Effect of Ghrelin  
  Current research has shown that there is an association 
between systemic ghrelin levels and cardiovascular indexes 
[38]. In healthy volunteers and patients with chronic conges-
tive heart failure (CHF), ghrelin can decrease peripheral 
vascular resistance, resulting in an increase in cardiac index 
and stroke volume [25, 39]. Ghrelin also can improve 
ventricular remodeling [40, 41], decrease cardiac injury 
induced by ischemia/reperfusion (I/R) [42] and isoprenaline 
[43] and reduce infarct size [44]. In vitro, ghrelin decreases 
inotropism [45, 46] and lusitropism [46], protects cardio-
myocytes from apoptpsis [20]. In addition, GH is indispen-
sable for the maintenance of heart structure and function, so, 
ghrelin also has an indirect cardio-protective effect. 
GHRELIN AND CARDIOVASCULAR DISEASES 
1) Ghrelin and Coronary Atherosclerotic Heart 
DiseaseCAD 
  Single nucleotide polymorphisms (SNPs) analyses in 
human suggests that specific haplotypes of the ghrelin ligand 
and its receptor act epistatically to affect susceptibility or 
tolerance to myocardial infarction (MI) and/or CAD [47]. 
Among CAD patients, those with variant genotypes 
(Leu72Met and Met72Met) had lower body mass index 
(BMI) than Leu72Leu carriers [48], however, the prepro-
ghrelin Leu72Met polymorphism is not associated with CAD 
in the Chinese population. Studies involving ghrelin’s role in 
CAD fall under three major categories: 
a) Regulation of Atherosclerosis  
  One study showed that the plasma concentration of 
ghrelin had a positive correlation with development of 
carotid artery atherosclerosis in males, but not in females 
[49]. Animal studies suggest that ghrelin receptors were 
significantly up-regulated (3-4 fold) in both atherosclerotic 
coronary arteries and saphenous vein grafts with advanced 
intimal thickening, when compared with normal vessels [50, 
51]. However, a research on kidney transplant patients 
demonstrates that lower plasma ghrelin concentration is an 
independent marker for abnormalities in glucose homeo-
stasis, which is related to greater carotid intima-media 
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for atherosclerosis. Furthermore, findings in older subjects 
with MS demonstrate that cIMT is significantly inversely 
correlated with ghrelin levels [53] and in elderly hyper-
tensives des-acyl ghrelin had a significant inverse correlation 
with cIMT [54]. On the whole, ghrelin and its receptors 
participate in the occurrence and development of the 
atherosclerotic process, and elevations of both levels may 
represent a compensatory mechanism to reverse the process, 
while, in kidney transplant patients and older people with 
MS or hypertension, this compensatory ability may be lost or 
damaged, of course, this deduction need further confir-
mation. 
  So far, the potential regulating mechanism of ghrelin on 
atherosclerosis is not clear. Endothelial dysfunction is consi-
dered to be one of the earliest events of the atherosclerotic 
development. In patients with endothelial dysfunction, 
plasma ghrelin level decreases [55]; conversely, the appli-
cation of exogenous ghrelin can improve endothelial dys-
function in MS patients by increasing nitric oxide bioactivity 
[34]. In addition, atherosclerosis is linked to inflammation 
and immunological reaction. Studies found that, ghrelin can 
inhibit proinflammatory cytokine pro-duction, mononuclear 
cell binding, and nuclear factor-kappa B(NF-B) activation 
in human endothelial cells in vitro as well as endotoxin-
induced cytokine production in vivo [36], moreover, 
exogenous ghrelin may significantly inhibit TNF-/ 
interferon--induced CD40 expression in HUVEC cells in a 
concentration-dependent manner [56]. These novel 
antiinflammatory and immunoregulatory actions of ghrelin 
may play a further modulatory role in atherosclerosis. In 
addition, in obese subjects low circulating levels of active 
ghrelin may enhance oxidative stress and the process of 
atherosclerosis [57], hence, ghrelin, through its anti-oxida-
tive effects, may attenuate atherosclerosis. However, ghrelin 
in pathophysiologic concentrations, as seen in patients with 
anorexia nervosa, Prader-Willi syndrome, and type 2 
diabetes, increases endothelial cell adhesion molecule (inter-
cellular adhesion molecule-1, ICAM-1; vascular cell adhe-
sion molecule-1,VCAM-1) expression, possibly contributing 
to increased atherosclerosis risk in such subjects [58]. 
Therefore, elucidation of the precise mechanism by which 
ghrelin regulates atherosclerosis may provide key insights 
into ghrelin’s administration in atherosclerosis therapy. 
b) Protective Effect of Ghrelin on Myocardial I/R Injury 
  Administration of ghrelin during reperfusion has been 
demonstrated to protect the myocardium against I/R injury, 
including reduced myocardial release of lactate dehydro-
genase and myoglobin, with subsequent improvements in 
coronary flow, heart rate, left ventricular systolic pressure, 
and left ventricular end-diastolic pressure [42]. The 
cardioprotective effects of ghrelin are independent of growth 
hormone release and likely involve binding to cardiovascular 
receptors, a process that is up regulated during I/R [42]. The 
direct protective effect of ghrelin against I/R is at least 
partially mediated by inhibiting myocardial endoplasmic 
reticulum stress (ERS) (data in press).   
  One study showed that ghrelin can dose-dependently 
increase coronary perfusion pressure in isolated perfused rat 
hearts and constrict isolated coronary arterioles, and this 
coronary vasoconstrictive action is dependent on Ca
2+ and 
protein kinase C (PKC) [33]. Another study reported that, in 
anesthetized pigs, intracoronary infusion of ghrelin induced 
coronary artery contraction, thereby reducing coronary 
circulation and the mechanism of this response has been 
shown to involve the inhibition of beta2-adrenergic mediated 
release of NO [32]. Thus, the exact ghrelin effects on 
coronary perfusion are inconclusive at present. Nonetheless, 
the beneficial effects of ghrelin on isolated I/R heart may yet 
indicate a potential role for this peptide in prevention of I/R 
injury.  
c) Potential Benefits in MI 
  Plasma C-ghrelin (66 carboxyl-terminal amino acids of 
pro-ghrelin) and ghrelin levels significantly decrease after 
MI [59]. While, ghrelin administration significantly reduced 
infarct size in isolated working rat hearts; the cardio-
protective effect is independent of growth hormone and may 
be related to PKC activation [44]. Moreover, in post-MI rats, 
acute administration of ghrelin (100 g/kg sc, twice daily, 
for 2 wk), compared with saline controls, left ven-
tricleLVend-diastolic pressure and LV enlargement were 
substantially less; the peak rate of rise and fall of LV 
pressure significantly increased; the increase in morpho-
metrical collagen volume fraction in the non-infarct regions 
were attenuated, accompanied by suppression of collagen I 
and III mRNA levels; the MI-induced increases in heart rate 
and plasma norepinephrine concentration were dramatically 
suppressed; and lastly, in this model, the ratio of low-to-high 
frequency spectra of heart rate variability was likewise 
attenuated [60]. Thus, future clinical trials are needed to 
reveal the potential role of ghrelin in improvement of post-
MI prognosis. 
2) Ghrelin and Hypertension 
  Some recent data have implicated reduced plasma ghrelin 
levels in patients with hypertension [61]. Low-level of 
ghrelin has been independently associated with elevated 
blood pressure (BP) [61]. The ghrelin Arg51Gln mutation, 
which is associated with low plasma ghrelin concentration, 
may be a risk factor for development of hypertension [62]. 
Moreover, SNPs analyses in subjects with impaired glucose 
tolerance has demonstrated the association of several ghrelin 
gene variations with BP levels [63]. However, in obese 
women, ghrelin was positively associated with hypertension; 
and this association was inversely influenced by the increase 
of BMI [64]. Therefore, the exact relationship between 
obesity, hypertension and ghrelin awaits further elucidation. 
Pregnant, spontaneously hypertensive rats (SHR) exhibit 
significantly higher plasma ghrelin levels when compare 
with those of pregnant or normotensive Wistar-Kyoto 
(WKY) animals. In contradistinction, the mRNA of ghrelin 
in the placenta of SHR was lower than that of normotensive 
rats, suggesting a possible association of ghrelin and 
hypertension during pregnancy [65]. Makino and colleagues 
investigated the ghrelin concentrations in plasma of non-
pregnant women, normal pregnant women, patients with 
pregnancy-induced hypertension, and postpartum women 
and they reported a negative correlation between plasma 
ghrelin concentration and systemic BP in normal pregnant 
women. Conversely, women with pregnancy-induced 
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those of normal pregnant women, and there is a significant 
correlation between plasma ghrelin levels and systemic BP 
[66]. These data suggest that the potential relationship 
between ghrelin and hypertension in women may differ 
depending on the gravid state.  
  As a potent vasodilator, ghrelin can decrease BP. 
Exogenous administration of both ghrelin and non- acyl-
ghrelin revealed endothelium-independent angioectatic 
potency and efficacy in reversing ET-1 induced constriction 
in human isolated arteries [19]. Furthermore, intravenous 
ghrelin injection has been shown to significantly decrease 
MAP in humans [25], suggesting a potential therapeutic role 
in hypertension.  
  The exact BP regulatory mechanism by ghrelin is 
unknown but may involve central and peripheral pathways.  
In the brain, ghrelin has been demonstrated to suppress 
sympathetic activity and decrease BP [67]. Additionally, 
ghrelin, when incubated with isolated SHR aortas, can supp-
ress vascular oxidative stress, thereby improve hypertension 
[68]. Modulation of endothelial function, as discussed 
previously, may be at least partially responsible for the anti-
hypertensive actions of ghrelin. In addition, another study 
suggested that the calcium-activated potassium-channel may 
play a key role in ghrelin-evoked decreases in MAP, 
especially in situations of endothelial dysfunction associated 
with paucity of nitric oxide [69].  
3) Ghrelin and Cardiomyopathy  
  Early studies focused on the protective effect of recom-
binant GH and insulin-like growth factor-1 (IGF-1) in 
cardiomyopathy [70], including ischemic cardiomyopathy, 
dilated cardiomyopathy (DCM), and tachycardia induced 
cardiomyopathy. In recent years, ghrelin and GHS are 
studied in this field. Chronic subcutaneous administration of 
ghrelin (100μg/kg, bid, three weeks) can improve LV dys-
function and attenuate the development of LV remodeling 
[40]. Administration of synthetic GSH, such as hexarelin and 
GHRP-6, have also demonstrated improvements in patients 
and animals with ischemic cardiomyopathy or dialated 
cardiomyopathy (DCM), independent of IGF-1 [71-75]. 
However, the role of ghrelin in the treatment of acromegaly-
induced cardiomyopathy remains controversial [76]. 
  At present, the therapeutic effects of ghrelin on 
cardiomyopathy are postulated to involve its inhibition of 
apoptosis of cardiomyocytes, by both GH-IGF-1-dependent 
[77] and–independent [20, 78, 79] pathways. Although with 
optimal therapy with angiotensin-converting enzyme inhi-
bitors, diuretics, digoxin, and beta-adrenergic receptor 
blockers, the average survival for cardiomyopathy sufferers 
with CHF is only three to five years [80]. Further work may 
reveal ghrelin to be a promising addition in our 
armamentarium against this formidable condition.    
4) Ghrelin and Drug-Induced Myocardial Injury 
  In rat models of isoproterenolISO[43] –or adriamy-
cinADR[81] –induced myocardial injury, endogenous 
plasma ghrelin levels increased significantly, perhaps due to 
a compensatory, self-protective mechanism. Moreover, 
administration of exogenous ghrelin can protect against ISO-
induced myocardial injury [43]; and in in vitro studies, 
ghrelin has shown to prevent against the cardio-toxicity of 
ADR [82]. The anti-ISO myocardial injury effects of ghrelin 
may be related to its inhibition of ET-1 [43], while its 
protective effects against ADR may be attributable to 
upregulation of TNF-/NF-B pathways as well as its  mito-
chondrial stabilization properties [82]. Thus far, however, 
definitive data regarding therapeutic benefits in drug-induced 
cardiomyopathies remain lacking.   
5) Ghrelin in Congenital Heart Diseases and Pulmonary 
Hypertension (PH) 
  One study reported that, in patients with congenital heart 
diseases, serum ghrelin levels are significantly higher than 
those of controls and correlated with TNF- levels [83]. The 
increased ghrelin levels may be related to malnutrition and 
growth retardation, and the correlation of ghrelin and 
cytokines may be associated with CHF and chronic shunt-
induced hypoxemia [83]. Whether ghrelin can affect 
formation of the heart tube and development of the embryo 
heart is not known.  In chronically hypoxic rats, daily sub-
cutaneous ghrelin injection (150 μg/kg) for two weeks  can 
significantly attenuate the development of PH, pulmonary 
vascular remodeling, right ventricular (RV) hypertrophy, and 
overexpression of eNOs and ET-1, as compared with saline 
control group [84]. In a rat model of monocrotaline (MCT)-
induced PH, endogenous ghrelin expression increased in RV 
myocardium, while exogenous administration of ghrelin 
attenuated PH, RV hypertrophy, peripheral pulmonary 
arterial wall thickness, RV diastolic impairment, and LV 
dysfunction [41].  
6) Ghrelin and Peripheral Vascular Disease 
  Ghrelin has been observed to retard vascular calci-
fication. The aortic calcification induced by vitamin D3 and 
nicotine, as well as VSMC calcification induced by beta-
glycerophosphate, are significantly attenuated by ghrelin 
[85]. In addition, ghrelin inhibits the angiotensin-II induced 
HAEC migration by increasing intracellular concentration of 
cAMP [37], which may further be involved in the prevention 
of the vascular calcification process. Ghrelin has been 
reported to suppress high glucose-induced vascular endo-
thelial cell (ECV-304) apoptosis by activating PI3K/Akt 
pathways and reducing ROS generation [35]. This effect of 
ghrelin may be useful in the prevention of diabetic vascular 
complications, especially in obese patients. In addition, as 
mentioned above, ghrelin is also involved in the regulation 
of peripheral atherosclerosis.  
7) Ghrelin and Heart Failure (HF) 
  Studies have suggested multi-protective effects of ghrelin 
on heart failure. 
a) Improvement in Cardiac Function  
  Animal experiments show that ghrelin can evoke 
significant decrease in MAP in normal, CHF, and GH 
deficient rats [40], and similar effects is observed in humans: 
in healthy volunteers and patients with CHF, ghrelin can 
decrease vascular resistance, increase cardiac index and 
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vasodilatory effect, as well as inhibition of the sympathetic 
activity [86]. While, Wiley and co-investigators outlined its 
endothelium-independent vasodilative properties and its 
antagonistic action against ET-1 [31]. And correlation has 
been observed between ghrelin levels and cardiac index [38], 
and Enomoto et al. reported that ghrelin can dose-depen-
dently increase stroke volume, cardiac index, and LVdp/dtmax 
in the absence of significant changes in heart rate [87]. 
However, neither ghrelin nor non- acyl-ghrelin has 
demonstrated effects on contractile force in paced atria [19], 
and  in vitro studies failed to show a direct increase in 
contractility of cardiomyocytes [88], thus, ghrelin-associated 
improvements in cardiac function may be attributed to 
afterload reduction and its stimulation of secretion of GH, a 
myocardial stimulant.  
  In addition, ghrelin has been noted to exert suppressive 
effects on  papillary muscle contraction and relaxation in rats 
with MCT-induced right ventricular hypertrophy [88]. 
Moreover, in both normal and hypertrophied myocardial 
cells, ghrelin inhibits contraction, relaxation and premature 
relaxation [46], so ghrelin may also improve myocardial 
function by reducing myocardial oxygen consumption. 
b) Anti-Cardiac Cachexia Effect of Ghrelin 
Prevention, or at least postponement, of the process of 
cachexia is a basic strategy in the treatment of heart failure 
[89]. Although non-cachectic CHF patients demonstrate a 
normal ghrelin level, plasma ghrelin is significantly higher in 
CHF patients with cachexia (heart failure for more than six 
months, a non-edemetous and unintentional weight loss over 
6% of the baseline weight) [90]. Cardiac cachexia, charac-
terized by weight loss and muscle consumption, is often 
observed in end-stage CHF and is a strong independent risk 
factor for mortality in these individuals. In CHF rats treated 
with ghrelin, appropriate weight gain and muscle/bone ratio 
can be maintained [40]. The mechanism may be attributed to 
the following ghrelin properties: appetite stimulation; 
enhanced fat and carbohydrate metabolism, resulting in 
positive energy balance; increased secretion of GH and IGF-
1, both of which can promote anabolic proliferation of skele-
tal and cardiac muscle. Ghrelin exerts a generalized anti-
catabolic effect in a variety of diseases. Aside from its 
classic regulation of appetite and fat metabolism, ghrelin 
also plays an important role in the regulation of fat-free mass 
[91]. 
c) Inhibition of Myocardial Apoptosis and Improvement of 
Ventricular Remodeling 
   It is also observed that in pressure overload rats with 
heart failure the application of synthetic peptide GHS 
(GHRP-1, 2, 6, hexarelin) can protect myocardial cells 
against apoptosis, with the increase of GHS-R1a [92]. 
Furthermore, in vitro data suggest that hexarelin can inhibit 
angiotensin-II (AngII)-induced myocardial apoptosis [79]. 
On these grounds, we speculate that ghrelin may also play 
anti-myocardial apoptosis role through the GHS-R1a. In 
addition, Bedendi, and coauthors reported, the acyl-ghrelin 
and non- acyl-ghrelin prevented cardiac myocyte apoptosis 
through the activation of ERK-1/2 and Akt [20], perhaps 
mediated through a new receptor distinct from 1a and 1b 
subtypes. 
  Early studies have shown that both GH and IGF-1 are 
necessary for cardiac and skeletal muscle growth as well as 
energy homeostasis [93, 94]. While, in patients with GH-
deficiency, there are deficiencies in cardiac muscle mass and 
diastolic filling. Furthermore, addition of GH may be 
beneficial to the CHF patients' cardiac structure and function 
[95-97]. Experiments have shown that, in CHF rats, ghrelin 
administration (100μg/kg, bid3 weeks) can increase plasma 
IGF-1 and long-term administration of ghrelin can increase 
ventricular posterior wall thickness, delay progression of LV 
dilatation, and decrease wall stress [40]. So it is postulated 
that ghrelin may inhibit ventricular remodeling through the 
GH-IGF-1. Intravenous ghrelin administration to CHF 
patients for 3 weeks has been shown to increase LV ejection 
fraction (LVEF), LV mass, [40] maximal exercise tolerance, 
and maximal oxygen consumption, while decrease LV end-
diastolic volume [98]. 
  Ghrelin can improve ventricular remodeling after MI [60] 
and reduce the diameter of cardiac muscle fibers in RV 
hypertrophy induced by PH [99]. Fibroblast proliferation and 
collagen synthesis, integral components in the detrimental 
process of myocardial remodeling, are inhibited in vitro by 
hexarelin in rat cardiomyocytes [100]. Given the possible 
common receptor of the two molecules, ghrelin may also 
have comparable properties. Hence, we have reason to 
believe that, ghrelin improve ventricular remodeling by GH-
dependent and independent pathways. 
d) Anti-Neuroendocrine Effect of Ghrelin 
  Ghrelin has been shown to exert direct suppression of 
central nervous system sympathetic output [86, 101] and the 
concentration of norepinephrine in patients with CHF [98].  
In pressure overload rats, the peptide GHS (GHRP-1, 2,6, 
hexarelin) can significantly inhibit CHF-induced increase in 
catecholamine, renin-angiotensin II, aldosterone, ET-1 and 
atrial natriuretic polypeptide [92]. So, we deduce that ghrelin 
may also have the similar effects. 
e) Anti-Inflammatory and Anti-Oxidative Effects 
  CHF is a complex syndrome, the pathophysiology of 
which involves neuroendocrine activation, heightened 
inflammatory response, and increased oxidative stress [102]. 
Experiments have proved that, ghrelin, both in vivo and in 
vitro has anti-inflammatory effect [36]. In addition, 
extensive data have confirmed ghrelin’s role in the anti-
oxidation. Ghrelin pre-incubation of aortic segments from 
SHR has demonstrated attenuation in vascular superoxide 
production and NAD(P)H oxidase activity [68]. Ghrelin 
reperfusion could decrease the content of lipid peroxidation 
product malondialdehyde in myocardium of I/R in rat hearts 
[42]. Moreover, ghrelin’s anti-oxidative effect has also been 
confirmed in studies in digestive [103, 104], nervous [105] 
and endocrine [106] systems. Therefore, these functions may 
be responsible for the beneficial action of ghrelin in heart 
failure. 
8) Ghrelin and the Metabolic Risk Factors of 
Cardiovascular System  
  It is well known that type 2 diabetes and MS are risk 
factors of many cardiovascular diseases. In humans acyl-
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opposite effects and ghrelin seems to have diabetogenic 
effects [107]. Low plasma concentrations of ghrelin are 
associated with several components of the MS, such as 
obesity and insulin resistance, however, ghrelin infusion 
acutely induces lipolysis and insulin resistance in human 
[108]. Hence, it seems that ghrelin has no good effect on 
these cardiovascular risk factors like MS and the cardio-
vascular benefit of people with these risk factors needs 
further studies. 
CARDIOVASCULAR PROTECTIVE EFFECTS AND 
PATHWAYS 
  According to the available data, mechanisms by which 
ghrelin carries out its cardiovascular protective effects are 
relatively complicated, and can be classified as GH depen-
dent pathway and GH independent pathway. The cardio-
vascular protective effects and the according mechanisms are 
summarized in Table 1.  
 
Table 1.  Ghrelin’s Cardiovascular Protective Effects and According Mechanisms 
Disease Protective  Effect  Mechanism 
CAD Regulation  of  atherosclerosis  GH independent pathway:  1) improve endothelial dysfunction 
   2) antiinflammatory action 
     3) immunoregulatory action 
 
Protective effect of ghrelin on myocardial 
I/R injury 
GH independent pathway: 
1) inhibit  myocardial endoplasmic reticulum 
stress 
     2) increase coronary perfusion? 
     3) anti-oxidative effects 
  4) improve myocardial  metabalism? 
 Potential benefits in MI  GH independent pathway:  1) inhibit myocardial apoptosis (probablely) 
   2) inhibit myocardial fibrosis (probablely) 
hypertension   GH independent pathway:  1) vasodilation 
  2) suppress vascular oxidative stress 
   3) modulate of endothelial function 
   4) suppress sympathetic nervous system 
cardiomyopathy   GH dependent pathway  inhibit myocardial apoptosis 
 GH independent pathway:  1) inhibit myocardial apoptosis (maybe) 
   2) improve ventricular remodeling 
drug-induced 
myocardial injury 
 GH independent pathway  1) inhibit myocardial apoptosis 
     2) anti-oxidative effect 
     3) Anti-inflammatory  effect 
pulmonary 
hypertension 
 GH independent pathway:  1) attenuate pulmonary arterial hypertension 
  2) decrease RV hypertrophy 
peripheral 
vascular disease 
 GH independent pathway:  retard vascular calcification 
   regulation of peripheral atherosclerosis. 
heart failure  Improvement in cardiac function  GH independent pathway:  1vasodilation 
  2) reducing myocardial oxygen consumption 
 Anti-cardiac cachexia effect of ghrelin  GH independent pathway:  1) appetite stimulation; 
   2) enhance fat and carbohydrate metabolism 
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Disease Protective  Effect  Mechanism 
   3) antiinflammatory action 
   4) anti-oxidative effects 
 GH dependent pathway 
promote anabolic proliferation of skeletal and 
cardiac muscle 
  Improvement of ventricular remodeling  GH independent pathway:  1) anti-myocardial apoptosis 
   2) inhibit myocardial fibrosis 
   GH dependent pathway  1) promote cardiac and skeletal muscle growth 
    2) anti-myocardial apoptosis 
 Anti-neuroendocrine effect of ghrelin  GH independent pathway:  suppress sympathetic nervous system 
 
CONCLUSION 
  In summary, there is robust data supporting an asso-
ciation between ghrelin and various cardiovascular condi-
tions, and some common processes such as inflammation, 
oxidative stress, and ERS have been implicated, although the 
exact mechanisms have not been fully elucidated. Preli-
minary studies have suggested this novel peptide has a 
promising prospect. To date, no adverse effect of this peptide 
has been reported, although further investigations are needed 
to define any potential therapeutic roles. In future, to 
approach the in-depth mechanisms of ghrelin in cardio-
vascular homeostasis regulation will be the investigative 
focal point. 
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